-
公开(公告)号：US20240350576A1
公开(公告)日：2024-10-24
申请号：US18618666
申请日：2024-03-27
发明人： Hyun Woo JEONG , Jinoh Chung , Wanki Kim , Jong Hwa Roh
CPC分类号： A61K36/82 , A61K38/011
摘要： The present disclosure relates to a method for lowering blood sugar including administering an effective amount of a green tea peptide composition to a subject in need thereof, and specifically, the green tea peptide composition according to the present disclosure exhibits a blood sugar-lowering effect through excellent stimulation of glucose transport in adipocytes, inhibition of gluconeogenesis in hepatocytes, and DPP-4 inhibitory activity, and can be applied to various health functional food compositions and pharmaceutical compositions.
-
2.发明公开公开(公告)号：US20240207351A1
公开(公告)日：2024-06-27
申请号：US18596274
申请日：2024-03-05
申请人： GEORGE D. PETITO
发明人： GEORGE D. PETITO
CPC分类号： A61K38/014 , A61K8/65 , A61K9/0056 , A61K45/06 , A61Q19/08
摘要： A tissue repair and wound healing composition with low molecular weight hydrolyzed collagen is provided. The wound healing composition with low molecular weight hydrolyzed collagen is a medicinal composition for facilitating the growth, protection and healing of tissues and cells in animals and humans. The main ingredient of the formulated composition is hydrolyzed collagen having a molecular weight of less than 499 Da, which can be combined with polysulfated glycosaminoglycans, hyaluronic acid or salts thereof, or a glucosamine salt, and mixtures thereof. The composition may include hydrolyzed collagen from multiple sources, such as bovine sourced hydrolyzed collagen or marine sourced hydrolyzed collagen and may further include hydrolyzed whey.
-
公开(公告)号：US11925192B2
公开(公告)日：2024-03-12
申请号：US14969519
申请日：2015-12-15
申请人： WELLDRINKS LTD
发明人： Alexander Evgenievich Kamcharov , Martin Seele , Tihomir Georgiev Yovchev , Yavor Nikolaev Draganov , Jurgen Pieck , Christian Schrobsdorff
IPC分类号： A23L2/66 , A23L2/44 , A23L2/52 , A23L2/54 , A23L2/56 , A23L2/58 , A23L2/60 , A23L2/68 , A61K8/65 , A61K9/00 , A61K38/01 , A61K38/39 , A61Q19/00 , A61Q19/08
CPC分类号： A23L2/66 , A23L2/44 , A23L2/52 , A23L2/54 , A23L2/56 , A23L2/58 , A23L2/60 , A23L2/68 , A61K8/65 , A61K38/014 , A61K38/39 , A61Q19/007 , A61Q19/08 , A23V2002/00 , A61K9/0095 , A61K2800/92
摘要： The present invention concerns a beverage having water and a concentration range of about 0.001 grams per liter to 8.44 grams per liter of collagen, wherein the collagen is hydrolyzed. The collagen concentration range may be between 1 milligram per liter to about 8440 milligram per liter or 1 parts per million to about 8440 parts per million. The hydrolyzed collagen has collagen peptides. The collagen peptides are produced through hydrolysis of a plurality of collagen sources. The plurality of collagen sources are derived from at least one of animal raw materials, animals raised in non-organic or organic farms, animals from various animal species and various parts of the animal carcass. The water may be comprised of at least one of tap water, spring or mineral water, and iceberg or glacier water.
-
公开(公告)号：US11890314B1
公开(公告)日：2024-02-06
申请号：US17813480
申请日：2022-07-19
申请人： NOVEL PHARMA INC.
发明人： Dong Kyu Jin
CPC分类号： A61K38/012 , A61K9/0021 , A61K38/1709 , A61K47/548 , A61P19/00 , A61P21/00
摘要： The present disclosure relates to a pharmaceutical composition for treating, preventing and/or ameliorating spinal muscular atrophy (SMA) and a method of administration thereof. A pharmaceutical composition for treating, preventing and/or ameliorating SMA according to an embodiment of the present disclosure may comprise a SMN protein, which is the cause of the onset of SMA. The pharmaceutical composition may be administered directly to a subject suffering from SMA via intracerebroventricular, intrathecal or intra-cisterna magna administration, thereby treating or preventing SMA or ameliorating symptoms of SMA. The pharmaceutical composition for treating, preventing or ameliorating SMA according to one embodiment of the present disclosure is safe, cost-effective and/or accessible compared to other previously approved drugs and can achieve substantially equivalent therapeutic effects.
-
公开(公告)号：US20230355704A1
公开(公告)日：2023-11-09
申请号：US18330109
申请日：2023-06-06
申请人： Nuritas Limited
发明人： Nora KHALDI , Cyril Lopez , Alessandro Adelfio
IPC分类号： A61K8/64 , A61F13/00 , A61Q19/08 , C12N9/02 , A61P17/02 , A61K38/01 , C07K14/415 , A61P35/00 , A61K9/00
CPC分类号： A61K38/01 , A61F13/00063 , A61K8/64 , A61K9/0014 , A61K38/011 , A61P17/02 , A61P35/00 , A61Q19/08 , C07K14/415 , C12N9/0069 , C12Y113/11012 , A61K38/00
摘要： A natural peptide comprising a cellular growth promoting fragment of a protein selected from SEQ ID NO’s: 1 to 13, and a composition comprising a plurality of growth promoting peptides, is described. Also disclosed is the use of the peptides and compositions in prevention of ageing of human skin, treatment of diseases or conditions characterised by damaged epithelial cells or tissue such as colon cancer and peripheral inflammatory disorders, and wound treatment. Specific pea and rice protein derived peptides are described in SEQ ID NO’s: 15 to 505, and 546 to 704.
-
6.发明公开公开(公告)号：US20230321175A1
公开(公告)日：2023-10-12
申请号：US17716189
申请日：2022-04-08
发明人： Abdu ADEM , Mariyam KHALID , Juma AL KAABI , Naheed AMIR , Samir ATTOUB
CPC分类号： A61K36/81 , A61P43/00 , A61K31/215 , A61P21/00 , A61K38/28 , A61K38/012
摘要： Embodiments of the present disclosure include compositions and methods for treating type 2 diabetes using anti-diabetic steroidal lactones of Withania Coagulans, such as Coagulansin A and derivatives and analogues thereof are described. For example, a method of treating type 2 diabetes in a subject in need thereof, the method comprising administering a therapeutically effective amount of Coagulansin A or a derivative or analogue thereof to the subject is provided. Further described embodiments include compositions and methods of treating muscle atrophy in a subject with type 2 diabetes by initiating regeneration of diseased skeletal muscle myoblasts using anti-diabetic steroidal lactones of Withania Coagulans.
-
公开(公告)号：US11759479B2
公开(公告)日：2023-09-19
申请号：US17221645
申请日：2021-04-02
申请人： Ohm Creations, LLC
发明人： Ruth Reynolds
IPC分类号： A61K33/32 , A61K8/02 , A61K8/04 , A61K8/19 , A61K9/00 , A61K9/06 , A61K9/16 , A61Q19/08 , A61K38/01
CPC分类号： A61K33/32 , A61K8/0225 , A61K8/042 , A61K8/19 , A61K9/0014 , A61K9/0053 , A61K9/0073 , A61K9/06 , A61K9/16 , A61K38/014 , A61Q19/08
摘要： Compositions comprising a manganese mineral are provided. In specific embodiments, the manganese mineral contains manganese carbonate (MnCO3), which may be in the form of rhodochrosite. The compositions may be administered topically to a subject, or in some versions by inhalation. For example, the compositions may be administered by direct contact with the subject's skin or by inhalation through the subject's nasal passages or mouth. Such application of the disclosed compositions may increase the subject's collagen synthesis, prolidase activity (an enzyme responsible for collagen function), and manganese superoxide dismutase activity (an antioxidant having manganese in its active site) in the subject.
-
公开(公告)号：US11752123B2
公开(公告)日：2023-09-12
申请号：US17157139
申请日：2021-01-25
发明人： Todd Henderson , David Griffin , David Bledsoe
IPC分类号： A61K31/198 , A61K36/756 , A61K38/01 , A61K45/06 , A61K31/7076 , A61K9/00 , A61K31/197 , A61K31/4045 , A61K36/575 , A61K38/38
CPC分类号： A61K31/198 , A61K9/0053 , A61K31/197 , A61K31/4045 , A61K31/7076 , A61K36/575 , A61K36/756 , A61K38/018 , A61K38/38 , A61K45/06 , A61K38/018 , A61K2300/00 , A61K38/38 , A61K2300/00 , A61K36/756 , A61K2300/00 , A61K36/575 , A61K2300/00 , A61K31/7076 , A61K2300/00 , A61K31/198 , A61K38/018
摘要： An anxiolytic composition includes a synergistic combination of one or more of an L-theanine, an s-adenosylmethionine (SAMe), and optionally an extract of Magnolia, an extract of Phellodendron, and a whey protein.
-
9.发明公开公开(公告)号：US20230241153A1
公开(公告)日：2023-08-03
申请号：US18164368
申请日：2023-02-03
发明人： Brandie Gowey
IPC分类号： A61K38/01 , A61K33/04 , A61K31/714 , A61K33/06 , A61K38/06 , A61K36/185 , A61K38/16
CPC分类号： A61K38/011 , A61K33/04 , A61K31/714 , A61K33/06 , A61K38/063 , A61K36/185 , A61K38/162
摘要： The fields of virology, oncology, and primary care need a drug that can upregulate expression of genes responsible for viral and abnormal cell clearance, such as p53 and those associated with or within the RNA interference (RNAi) process. It is well-known that cellular responses to viral genes and proteins, and indeed that of precancerous or cancerous cells, require the mechanistic efforts via p53 and the RNAi. Without the p53/RNAi activities, viral load and abnormal cell presence may remain or create disease processes and symptoms. The present invention features compositions (e.g., Sarravis® Core) and methods that allow for a decrease in viral and/or cancer cell expression through up regulation of RNAi, p53, and associated cofactors.
-
公开(公告)号：US20230173014A1
公开(公告)日：2023-06-08
申请号：US17997501
申请日：2021-02-09
发明人： Francisca Isabel BRAVO VÁZQUEZ , Raúl LÓPEZ FERNÁNDEZ , Juan María ALCAIDE HIDALGO , María MARGALEF JORNET , Anna MAS CAPDEVILA , Jose María DEL BAS PRIOR , María Eugenia HERNÁNDEZ DE PABLO , María Begoñia MUGUERZA MARQUÍNEZ
IPC分类号： A61K38/01 , C12N9/54 , A23L33/105 , A23L33/18 , A61P9/12
CPC分类号： A61K38/01 , C12N9/54 , A23L33/105 , A23L33/18 , A61P9/12
摘要： The present invention relates to wine lees and derivatives thereof. Likewise, it relates to their use in medicine.
-
-
-
-
-
-
-
-
-
搜索结果
825 条记录 (耗时 0.051 秒)
